Journal article
The effect of dupilumab on lung function parameters in patients with oral corticosteroid-dependent severe asthma
Abstract
Background In Phase 3 LIBERTY ASTHMA VENTURE (NCT02528214), add-on dupilumab reduced oral corticosteroid (OCS) use while reducing severe exacerbations and improving pre-bronchodilator (BD) forced expiratory volume in 1 s (FEV1) in OCS-dependent severe asthma patients. Objective This post hoc study evaluated dupilumab's efficacy based on several lung function parameters for the overall population and subgroups defined by baseline biomarkers. …
Authors
Rabe KF; Nair P; Maspero JF; Castro M; Rice MS; Deniz Y; Rowe P; Staudinger HW; Pirozzi G; Akinlade B
Journal
Respiratory Medicine X, Vol. 2, ,
Publisher
Elsevier
Publication Date
November 2020
DOI
10.1016/j.yrmex.2019.100010
ISSN
2590-1435